Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1161-1166

  Watanabe, N ^a   Matsumoto, K ^a   Muramatsu, H ^b   Horibe, K ^c   Matsuyama, T ^d   Kojima, S ^b   Kato, K ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d Nagoya Nishi Clinic Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MYELOABLATIVE CONDITIONING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; TREATMENT DURATION; VEIN OCCLUSION; ACUTE DISEASE; ADOLESCENT; BLOOD; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PREDICTIVE VALUE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE; TACROLIMUS; TREATMENT OUTCOME;

EID: 77955013706     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.327     Document Type: Article

References (12)

1. Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157-163.
2. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H et al. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLADRB1 and HLA-DQB1. Biol Blood Marrow Transplant 2000; 6: 190-197.
3. Morishima Y, Morishita Y, Tanimoto M, Ohno R, Saito H, Horibe K et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood 1989; 74: 2252-2256.
4. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
5. Przepiorka D, Nash RA, Wingard JR, Zhu J, Maher RM, FitzsimmonsWE et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 94-97.
6. Nishida T, Hamaguchi M, Hirabayashi N, Haneda M, Terakura S, Atsuta Y et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143-1150.
7. Fujino M, Kim Y, Ito M. Intestinal thrombotic microangiopathy induced by FK506 in rats. Bone Marrow Transplant 2007; 39: 367-372.
8. Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525-531.
9. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA et al. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 2007; 13: 469-477.
10. Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000; 26: 601-605.
11. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108-114.
12. Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. Transplant Proc 2005; 37: 1725-1727.